Journal Article
. 2020 Jan; 28(9):4413-4424.
doi: 10.1007/s00520-020-05295-2.

Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy

Prasad L Gawade 1 Shuling Li 2 David Henry 3 Nancy Smith 4 Rajesh Belani 5 Michael A Kelsh 6 Brian D Bradbury 6 
  • PMID: 31919669
  •     31 References
  •     2 citations


Purpose: To evaluate patterns of primary prophylactic (PP) granulocyte colony-stimulating factor (G-CSF) use following chemotherapy by cancer type and febrile neutropenia (FN) risk.

Methods: Using a commercial administrative database, we identified adult patients diagnosed with breast, colorectal, lung, ovarian cancer, or non-Hodgkin lymphoma (NHL) who initiated chemotherapy with high risk (HR) or intermediate risk (IR) for FN between January 1, 2013, and August 31, 2017. We describe use of PP-G-CSF, proportion completing all their cycles with pegfilgrastim, timing of pegfilgrastim, and duration of short-acting G-CSF.

Results: Among 22,868 patients (breast 11,513; colorectal 3765; lung 4273; ovarian 1287; and NHL 2030), 36.8% received HR and 63.2% received IR (64.4% of whom had ≥ 1 risk factor [RF] for FN). Proportions of patients receiving PP-G-CSF in the first cycle were 76.1%, 28.2%, and 26.4% among patients receiving HR, IR, and IR plus ≥ 1 RF, respectively. Among breast cancer patients receiving HR regimens and initiating PP-pegfilgrastim, 60.4% (95% confidence interval [CI] 57.2-63.6%) initiating via on-body injector (OBI) and 51.9% (95% CI 48.0-55.8%) initiating via prefilled syringe (PFS) completed all their cycles with OBI and PFS, respectively. Among all cycles with PP-PFS, 8.5% received PFS on the same day as chemotherapy completion. Mean administrations/cycle were 3.2 (standard deviation [SD] 2.3) for filgrastim, 3.0 (SD 1.6) for filgrastim-sndz, and 4.3 (SD 2.5) for tbo-filgrastim.

Conclusions: There is under- and mistimed use of PP-G-CSF among patients at HR for FN. Novel pegfilgrastim delivery devices could help breast cancer patients at HR for FN complete all their cycles with timely prophylaxis.

Keywords: Febrile neutropenia; Filgrastim; Granulocyte colony–stimulating factor; On-body injector; Pegfilgrastim; Prophylaxis.

Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database.
Romina Sosa, Shuling Li, +3 authors, Allan J Collins.
Support Care Cancer, 2017 May 01; 25(10). PMID: 28456908
Chimeric Antigen Receptor Therapy.
Carl H June, Michel Sadelain.
N Engl J Med, 2018 Jul 05; 379(1). PMID: 29972754    Free PMC article.
Highly Cited. Review.
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
M S Aapro, J Bohlius, +10 authors, European Organisation for Research and Treatment of Cancer.
Eur J Cancer, 2010 Nov 26; 47(1). PMID: 21095116
Highly Cited. Systematic Review.
Colony-stimulating factors for the management of neutropenia in cancer patients.
David C Dale.
Drugs, 2002 Dec 14; 62 Suppl 1. PMID: 12479591
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
John Marquart, Emerson Y Chen, Vinay Prasad.
JAMA Oncol, 2018 May 02; 4(8). PMID: 29710180    Free PMC article.
Highly Cited.
Early Adoption of Biosimilar Growth Factors in Supportive Cancer Care.
Xiaoxue Chen, Abiy Agiro, +2 authors, Michael Fisch.
JAMA Oncol, 2018 Nov 02; 4(12). PMID: 30383135    Free PMC article.
Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Lee S Schwartzberg, Lincy S Lal, +5 authors, Stephanie Korrer.
J Manag Care Spec Pharm, 2018 Apr 25; 24(10). PMID: 29687743
Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015.
Derek Weycker, Mark Bensink, +2 authors, David Chandler.
Curr Med Res Opin, 2017 Sep 30; 33(12). PMID: 28958156
Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
Arash Naeim, Henry J Henk, +4 authors, Robert Deeter.
BMC Cancer, 2013 Jan 10; 13. PMID: 23298389    Free PMC article.
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Derek Weycker, Xiaoyan Li, +3 authors, May Hagiwara.
Support Care Cancer, 2015 Nov 27; 24(5). PMID: 26607482    Free PMC article.
Time trends in utilization of G-CSF prophylaxis and risk of febrile neutropenia in a Medicare population receiving adjuvant chemotherapy for early-stage breast cancer.
Ravi K Goyal, Spiros Tzivelekis, +2 authors, James A Kaye.
Support Care Cancer, 2017 Sep 19; 26(2). PMID: 28921379
A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.
Carrie N Klabunde, Julie M Legler, +2 authors, Deborah Schrag.
Ann Epidemiol, 2007 May 29; 17(8). PMID: 17531502
Highly Cited.
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
F A Holmes, J A O'Shaughnessy, +10 authors, B C Liang.
J Clin Oncol, 2002 Feb 01; 20(3). PMID: 11821454
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Jeffrey Crawford, Pamela Sue Becker, +29 authors, Lenora Pluchino.
J Natl Compr Canc Netw, 2017 Dec 11; 15(12). PMID: 29223990
Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population.
Steven Kozlowski, Noy Birger, +4 authors, Jeffrey A Kelman.
JAMA, 2018 Sep 08; 320(9). PMID: 30193265    Free PMC article.
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
Nicole M Kuderer, David C Dale, Jeffrey Crawford, Gary H Lyman.
J Clin Oncol, 2007 Jul 20; 25(21). PMID: 17634496
Highly Cited. Systematic Review.
Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.
Derek Weycker, Mark Bensink, +2 authors, David Chandler.
Curr Med Res Opin, 2017 Sep 30; 33(12). PMID: 28958157
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Hagop Kantarjian, Anthony Stein, +23 authors, Max S Topp.
N Engl J Med, 2017 Mar 02; 376(9). PMID: 28249141    Free PMC article.
Highly Cited.
Pharmacovigilance in oncology.
Paolo Baldo, Giulia Fornasier, +2 authors, Sara Francescon.
Int J Clin Pharm, 2018 Aug 03; 40(4). PMID: 30069667    Free PMC article.
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Julie R Brahmer, Scott S Tykodi, +23 authors, Jon M Wigginton.
N Engl J Med, 2012 Jun 05; 366(26). PMID: 22658128    Free PMC article.
Highly Cited.
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
M D Green, H Koelbl, +12 authors, International Pegfilgrastim 749 Study Group.
Ann Oncol, 2002 Dec 19; 14(1). PMID: 12488289
Highly Cited.
Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level.
Hassam Baig, Barbara Somlo, +3 authors, Phuong K Morrow.
J Oncol Pharm Pract, 2018 Sep 12; 25(7). PMID: 30200842    Free PMC article.
Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer.
Scott D Ramsey, Jeannine S McCune, +4 authors, Sean D Sullivan.
Am J Manag Care, 2010 Sep 30; 16(9). PMID: 20873955
Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.
Hude Quan, Bing Li, +5 authors, Vijaya Sundararajan.
Am J Epidemiol, 2011 Feb 19; 173(6). PMID: 21330339
Highly Cited.
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.
Howard A Burris, Chandra P Belani, +6 authors, Alan Saven.
J Oncol Pract, 2010 Sep 03; 6(3). PMID: 20808556    Free PMC article.
Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.
Eric Tai, Gery P Guy, Angela Dunbar, Lisa C Richardson.
J Oncol Pract, 2017 Apr 25; 13(6). PMID: 28437150    Free PMC article.
Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
Maureen J Aarts, Frank P Peters, +17 authors, Vivianne C G Tjan-Heijnen.
J Clin Oncol, 2013 May 01; 31(34). PMID: 23630211
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Thomas J Smith, Kari Bohlke, +12 authors, American Society of Clinical Oncology.
J Clin Oncol, 2015 Jul 15; 33(28). PMID: 26169616
Highly Cited. Systematic Review.
Epidemiology of febrile neutropenia.
Gary H Lyman, Nicole M Kuderer.
Support Cancer Ther, 2008 Jul 17; 1(1). PMID: 18628128
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Identifying persons with diabetes using Medicare claims data.
P L Hebert, L S Geiss, +3 authors, A M McBean.
Am J Med Qual, 2000 Jan 07; 14(6). PMID: 10624032
Highly Cited.
Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product.
Aaron B Mendelsohn, James Marshall, +3 authors, Catherine M Lockhart.
Drugs Real World Outcomes, 2021 Feb 01; 8(2). PMID: 33517548    Free PMC article.
Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
Ahuva Averin, Amanda Silvia, +8 authors, Derek Weycker.
Support Care Cancer, 2020 Sep 04; 29(4). PMID: 32880732    Free PMC article.